A prognostic eight-gene expression signature for patients with breast cancer receiving adjuvant chemotherapy
- PMID: 31692061
- DOI: 10.1002/jcb.29550
A prognostic eight-gene expression signature for patients with breast cancer receiving adjuvant chemotherapy
Abstract
Breast cancer is a popularly diagnosed malignant tumor. Genomic profiling studies suggest that breast cancer is a disease with heterogeneity. Chemotherapy is one of the chief means to treat breast cancer, while its responses and clinical outcomes vary largely due to the conventional clinicopathological factors and inherent chemosensitivity of breast cancer. Using the least absolute shrinkage and selection operator (LASSO) Cox regression model, our study established a multi-mRNA-based signature model and constructed a relative nomogram in predicting distant-recurrence-free survival for patients receiving surgery and following chemotherapy. We constructed a signature of eight mRNAs (IPCEF1, SYNDIG1, TIGIT, SPESP1, C2CD4A, CLCA2, RLN2, and CCL19) with the LASSO model, which was employed to separate subjects into groups with high- and low-risk scores. Obvious differences of distant-recurrence-free survival were found between these two groups. This eight-mRNA-based signature was independently associated with the prognosis and had better prognostic value than classical clinicopathologic factors according to multivariate Cox regression results. Receiver operating characteristic results demonstrated excellent performance in diagnosing 3-year distant-recurrence by the eight-mRNA signature. A nomogram that combined both the eight-mRNA-based signature and clinicopathological risk factors was constructed. Comparing with an ideal model, the nomograms worked well both in the training and validation sets. Through the results that the eight-mRNA signature effectively classified patients into low- and high-risk of distant recurrence, we concluded that this eight-mRNA-based signature played a promising predictive role in prognosis and could be clinically applied in breast cancer patients receiving adjuvant chemotherapy.
Keywords: LASSO Cox regression; breast cancer; distant recurrence; multi-mRNA-based signature; nomogram.
© 2019 Wiley Periodicals, Inc.
Similar articles
-
A prognostic eight-lncRNA expression signature in predicting recurrence of ER-positive breast cancer receiving endocrine therapy.J Cell Physiol. 2020 May;235(5):4746-4755. doi: 10.1002/jcp.29352. Epub 2019 Oct 29. J Cell Physiol. 2020. PMID: 31663114
-
A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.Front Immunol. 2022 Nov 2;13:947802. doi: 10.3389/fimmu.2022.947802. eCollection 2022. Front Immunol. 2022. PMID: 36405735 Free PMC article.
-
A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer.Front Oncol. 2021 Sep 16;11:746763. doi: 10.3389/fonc.2021.746763. eCollection 2021. Front Oncol. 2021. PMID: 34604089 Free PMC article.
-
A 15-Gene Signature and Prognostic Nomogram for Predicting Overall Survival in Non-Distant Metastatic Oral Tongue Squamous Cell Carcinoma.Front Oncol. 2021 Mar 9;11:587548. doi: 10.3389/fonc.2021.587548. eCollection 2021. Front Oncol. 2021. PMID: 33767977 Free PMC article.
-
Association of the Collagen Signature in the Tumor Microenvironment With Recurrence and Survival of Patients With T4N0M0 Colon Cancer.Dis Colon Rectum. 2021 May;64(5):563-575. doi: 10.1097/DCR.0000000000001907. Dis Colon Rectum. 2021. PMID: 33538520
Cited by
-
MIRS: An AI scoring system for predicting the prognosis and therapy of breast cancer.iScience. 2023 Oct 26;26(11):108322. doi: 10.1016/j.isci.2023.108322. eCollection 2023 Nov 17. iScience. 2023. PMID: 38026206 Free PMC article.
-
A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma.Heliyon. 2022 Dec 23;8(12):e12648. doi: 10.1016/j.heliyon.2022.e12648. eCollection 2022 Dec. Heliyon. 2022. PMID: 36619423 Free PMC article.
-
Analysis of the regulatory mechanisms of prognostic immune factors in thyroid cancer.Front Oncol. 2022 Dec 14;12:1059591. doi: 10.3389/fonc.2022.1059591. eCollection 2022. Front Oncol. 2022. PMID: 36591507 Free PMC article.
-
Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients.Front Oncol. 2021 Aug 26;11:660242. doi: 10.3389/fonc.2021.660242. eCollection 2021. Front Oncol. 2021. PMID: 34513664 Free PMC article.
-
Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level.BMC Cancer. 2021 Aug 13;21(1):918. doi: 10.1186/s12885-021-08617-7. BMC Cancer. 2021. PMID: 34388989 Free PMC article.
References
REFERENCES
-
- World Health Organization. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 released by The International Agency for Research on Cancer (IARC). Periodical Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 released by The International Agency for Research on Cancer (IARC), September 12, 2018.
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
-
- O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20-29.
-
- Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113-126.
-
- Montemurro F, Perrone F, Geuna E. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:1672-1673.
LinkOut - more resources
Full Text Sources
